I'll be very brief.
Just to follow up on what Patrick said, if you are a drug developer and you're looking for a manufacturer, the answer is usually, “I will fit you in two years from now when I finish my current runs, which are driving my business bottom line.” What Gates could do—and I'm throwing this out there just as an idea—is to pre-purchase capacity in some of the CGMP-certified facilities that would allow researchers to get priority service. That would meet the original objective. There would be no need to build dedicated facilities here, and it would address one of the criteria in the original call, that the facility had to have three different platforms. You could pick three different manufacturers who had this expertise.
What it doesn't meet is the extra criterion that was in the call, which is flexibility with respect to adapting new technologies and new methods for vaccine production. That is where a more research-dedicated facility would be required.
So one partial solution would be to go with the existing manufacturers and to pre-purchase capacity, so there would be timely production of clinical trial candidates. But there still is a residual research need.